Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅳ
Status:
RECRUITING
Trial end date:
2026-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of intravenous tenecteplase (0.25 mg/kg) compared with standard therapy in patients with acute ischemic stroke presenting with mild symptoms-defined as a National Institutes of Health Stroke Scale (NIHSS) score ≤5 accompanied by persistent unilateral limb weakness or speech impairment within 4.5 hours of onset.